

Michel Komajda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3837280/publications.pdf>

Version: 2024-02-01

251
papers

42,932
citations

3731

89
h-index

2178

202
g-index

268
all docs

268
docs citations

268
times ranked

28936
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Torcetrapib in Patients at High Risk for Coronary Events. <i>New England Journal of Medicine</i> , 2007, 357, 2109-2122.	27.0	2,811
2	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020, 41, 255-323.	2.2	2,811
3	Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. <i>Lancet, The</i> , 2010, 376, 875-885.	13.7	2,119
4	Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). <i>European Heart Journal</i> , 2005, 26, 1115-1140.	2.2	1,986
5	Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. <i>Lancet, The</i> , 2003, 362, 7-13.	13.7	1,664
6	Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2008, 359, 2456-2467.	27.0	1,663
7	Rosuvastatin in Older Patients with Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2007, 357, 2248-2261.	27.0	1,330
8	Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. <i>Lancet, The</i> , 2009, 373, 2125-2135.	13.7	1,243
9	Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2003, 107, 2227-2232.	1.6	1,129
10	Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology. <i>European Heart Journal</i> , 2005, 26, 384-416.	2.2	1,114
11	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 117-128.	27.0	1,080
12	EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. <i>European Heart Journal</i> , 2006, 27, 2725-2736.	2.2	1,063
13	Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. <i>European Heart Journal</i> , 2015, 36, 657-668.	2.2	902
14	Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. <i>Lancet, The</i> , 2010, 376, 886-894.	13.7	769
15	Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. <i>European Heart Journal</i> , 2016, 37, 1850-1858.	2.2	757
16	Rosiglitazone Evaluated for Cardiovascular Outcomes – An Interim Analysis. <i>New England Journal of Medicine</i> , 2007, 357, 28-38.	27.0	729
17	State of the art: Using natriuretic peptide levels in clinical practice. <i>European Journal of Heart Failure</i> , 2008, 10, 824-839.	7.1	691
18	Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. <i>European Heart Journal</i> , 2005, 26, 1303-1308.	2.2	564

#	ARTICLE	IF	CITATIONS
19	Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. <i>Lancet</i> , The, 2009, 374, 1840-1848.	13.7	548
20	Atlas of the clinical genetics of human dilated cardiomyopathy. <i>European Heart Journal</i> , 2015, 36, 1123-1135.	2.2	456
21	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 853-872.	7.1	434
22	Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction. <i>Circulation</i> , 2011, 124, 2491-2501.	1.6	418
23	Cardiac myosin binding proteinâ€C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. <i>Nature Genetics</i> , 1995, 11, 438-440.	21.4	417
24	Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. <i>European Heart Journal</i> , 2005, 26, 1653-1659.	2.2	354
25	Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2007, 9, 684-694.	7.1	335
26	Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). <i>European Heart Journal</i> , 2006, 27, 1216-1222.	2.2	294
27	A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. <i>European Heart Journal</i> , 2011, 32, 1065-1076.	2.2	292
28	Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction. <i>Circulation</i> , 2010, 121, 1393-1405.	1.6	290
29	Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. <i>European Heart Journal</i> , 2011, 32, 2507-2515.	2.2	264
30	Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. <i>European Heart Journal</i> , 2008, 30, 478-486.	2.2	247
31	Clinical Features and Prognostic Implications of Familial Hypertrophic Cardiomyopathy Related to the Cardiac Myosin-Binding Protein C Gene. <i>Circulation</i> , 1998, 97, 2230-2236.	1.6	241
32	Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. <i>Critical Care Medicine</i> , 2008, 36, S129-S139.	0.9	240
33	Effects on Outcomes of Heart Rate Reduction by Ivabradine in Patients With Congestive Heart Failure: Is There an Influence of Beta-Blocker Dose?. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1938-1945.	2.8	233
34	Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. <i>European Heart Journal</i> , 2013, 34, 2149-2157.	2.2	225
35	Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 326-336.	1.6	222
36	Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 569-577.	3.9	219

#	ARTICLE	IF	CITATIONS
37	Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 27-35.	3.9	216
38	Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 239-248.	7.1	214
39	Evaluation of the effects of sodium-glucose cotransporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1279-1287.	7.1	205
40	Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. <i>European Heart Journal</i> , 2010, 31, 824-831.	2.2	203
41	Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. <i>European Journal of Heart Failure</i> , 2015, 17, 925-935.	7.1	203
42	The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. <i>European Heart Journal</i> , 2006, 27, 1440-1446.	2.2	201
43	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. <i>Circulation</i> , 2021, 144, 1284-1294.	1.6	195
44	Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. <i>European Journal of Heart Failure</i> , 2016, 18, 514-522.	7.1	193
45	Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the PRESERVE trial. <i>European Journal of Heart Failure</i> , 2008, 10, 149-156.	7.1	183
46	Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. <i>European Journal of Heart Failure</i> , 2017, 19, 1414-1423.	7.1	183
47	The Atrial Fibrillation Ablation Pilot Study: an European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. <i>European Heart Journal</i> , 2014, 35, 1466-1478.	2.2	180
48	Heart failure with preserved ejection fraction: a clinical dilemma. <i>European Heart Journal</i> , 2014, 35, 1022-1032.	2.2	178
49	Sex Differences in Clinical Characteristics and Outcomes in Elderly Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2012, 5, 571-578.	3.9	177
50	Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. <i>European Heart Journal</i> , 2011, 32, 2395-2404.	2.2	175
51	Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. <i>European Heart Journal</i> , 2005, 26, 2706-2713.	2.2	172
52	Evaluation of the effect of sodium-glucose cotransporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1270-1278.	7.1	155
53	Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. <i>European Heart Journal</i> , 2005, 26, 2259-2268.	2.2	154
54	Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1495-1503.	7.1	154

#	ARTICLE	IF	CITATIONS
55	Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2017, 135, 724-735.	1.6	153
56	Renal Dysfunction in Patients With Heart Failure With Preserved Versus Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2012, 5, 309-314.	3.9	152
57	Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>European Heart Journal</i> , 2012, 33, 2290-2296.	2.2	144
58	Diagnostic Value of Electrocardiography and Echocardiography for Familial Hypertrophic Cardiomyopathy in a Genotyped Adult Population. <i>Circulation</i> , 1997, 96, 214-219.	1.6	143
59	Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). <i>American Heart Journal</i> , 2009, 157, 271-277.	2.7	141
60	Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. <i>European Heart Journal</i> , 2016, 37, ehv481.	2.2	140
61	Molecular Basis of Familial Cardiomyopathies. <i>Circulation</i> , 1995, 91, 532-540.	1.6	140
62	A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy. <i>European Heart Journal</i> , 2014, 35, 1069-1077.	2.2	137
63	Mutation screening in dilated cardiomyopathy: prominent role of the beta myosin heavy chain gene. <i>European Heart Journal</i> , 2005, 26, 794-803.	2.2	135
64	Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. <i>European Journal of Heart Failure</i> , 2008, 10, 140-148.	7.1	134
65	Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes. <i>Circulation: Heart Failure</i> , 2010, 3, 314-325.	3.9	134
66	A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. <i>European Heart Journal</i> , 2008, 29, 816-824.	2.2	131
67	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 196-213.	7.1	131
68	Identification of two novel mutations in the ventricular regulatory myosin light chain gene (MYL2) associated with familial and classical forms of hypertrophic cardiomyopathy. <i>Journal of Molecular Medicine</i> , 1998, 76, 208-214.	3.9	130
69	The Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial: Rationale and Design. <i>Journal of Cardiac Failure</i> , 2005, 11, 576-585.	1.7	129
70	New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey. <i>European Heart Journal</i> , 2008, 29, 1618-1624.	2.2	127
71	Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. <i>European Heart Journal</i> , 2012, 33, 2813-2820.	2.2	126
72	The Benefits of Early Combination Treatment of Carvedilol and an ACE-Inhibitor in Mild Heart Failure and Left Ventricular Systolic Dysfunction. The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial (CARMEN). <i>Cardiovascular Drugs and Therapy</i> , 2004, 18, 57-66.	2.6	123

#	ARTICLE	IF	CITATIONS
73	Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A ω 1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. <i>European Journal of Heart Failure</i> , 2009, 11, 281-291.	7.1	120
74	Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. <i>European Heart Journal</i> , 2009, 30, 3015-3026.	2.2	117
75	The Influence of the Angiotensin I Converting Enzyme Genotype in Familial Hypertrophic Cardiomyopathy Varies with the Disease Gene Mutation. <i>Journal of Molecular and Cellular Cardiology</i> , 1997, 29, 831-838.	1.9	110
76	Genetic Association Study Identifies HSPB7 as a Risk Gene for Idiopathic Dilated Cardiomyopathy. <i>PLoS Genetics</i> , 2010, 6, e1001167.	3.5	110
77	Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 233-246.	2.6	108
78	Coenzyme Q10, Rosuvastatin, and Clinical Outcomes in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1196-1204.	2.8	105
79	Selective Heart Rate Reduction With Ivabradine Unloads the Left Ventricle in Heart Failure Patients. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1977-1985.	2.8	104
80	Characterization of a Unique Genetic Variant in the β 1-adrenoceptor Gene and Evaluation of its Role in Idiopathic Dilated Cardiomyopathy. <i>Journal of Molecular and Cellular Cardiology</i> , 1999, 31, 1025-1032.	1.9	103
81	Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I. <i>European Heart Journal</i> , 2007, 28, 1310-1318.	2.2	103
82	The current and future management of acute heart failure syndromes. <i>European Heart Journal</i> , 2010, 31, 784-793.	2.2	100
83	Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: an individual patient data meta-analysis. <i>European Journal of Heart Failure</i> , 2012, 14, 1139-1146.	7.1	100
84	Mutations in the Z-band protein myopalladin gene and idiopathic dilated cardiomyopathy. <i>Cardiovascular Research</i> , 2008, 77, 118-125.	3.8	99
85	Codon 102 of the Cardiac Troponin T Gene Is a Putative Hot Spot for Mutations in Familial Hypertrophic Cardiomyopathy. <i>Circulation</i> , 1996, 94, 3069-3073.	1.6	99
86	Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. <i>European Heart Journal</i> , 2004, 25, 1788-1796.	2.2	97
87	Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 601-612.	2.8	97
88	Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. <i>European Journal of Heart Failure</i> , 2018, 20, 1315-1322.	7.1	96
89	Exome-wide association study reveals novel susceptibility genes to sporadic dilated cardiomyopathy. <i>PLoS ONE</i> , 2017, 12, e0172995.	2.5	92
90	Relation of Peripheral Collagen Markers to Death and Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 561-568.	3.9	91

#	ARTICLE	IF	CITATIONS
91	Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I _f Inhibitor Ivabradine Trial (SHIFT). <i>European Journal of Heart Failure</i> , 2010, 12, 75-81.	7.1	88
92	Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2016, 18, 328-336.	7.1	88
93	Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. <i>European Journal of Heart Failure</i> , 2019, 21, 921-929.	7.1	86
94	Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. <i>European Journal of Heart Failure</i> , 2007, 9, 901-909.	7.1	85
95	Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. <i>European Heart Journal</i> , 2013, 34, 2263-2270.	2.2	85
96	Correlation Between Left Ventricular Hypertrophy and GAA Trinucleotide Repeat Length in Friedreich's Ataxia. <i>Circulation</i> , 1997, 95, 2247-2249.	1.6	83
97	Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (lâ€Preserve). <i>European Journal of Heart Failure</i> , 2014, 16, 778-787.	7.1	80
98	Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019, 12, e006539.	3.9	78
99	International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction. <i>Circulation</i> , 2015, 131, 43-53.	1.6	75
100	Effect of intracoronary administration of <sc>AAV1</sc>/<sc>SERCA2a</sc> on ventricular remodelling in patients with advanced systolic heart failure: results from the <sc>AGENTâ€HF</sc> randomized phase 2 trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1534-1541.	7.1	75
101	Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2000, 35, 29-35.	2.8	74
102	Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failureâ€COMET. <i>American Heart Journal</i> , 2005, 149, 370-376.	2.7	74
103	Clinical evaluation of cardiovascular devices: principles, problems, and proposals for European regulatory reform: Report of a policy conference of the European Society of Cardiology. <i>European Heart Journal</i> , 2011, 32, 1673-1686.	2.2	73
104	The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 429-441.	4.1	72
105	Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. <i>European Journal of Heart Failure</i> , 2002, 4, 321-329.	7.1	69
106	Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a ð€blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial. <i>European Journal of Heart Failure</i> , 2007, 9, 795-801.	7.1	69
107	A 22-Year Follow-up Study of Long-term Cardiac Outcome and Predictors of Survival in Friedreich Ataxia. <i>JAMA Neurology</i> , 2015, 72, 1334.	9.0	69
108	Worsening Renal Function and Outcome in Heart Failure Patients With Preserved Ejection Fraction and the Impact of Angiotensin Receptor Blocker Treatment. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1106-1113.	2.8	67

#	ARTICLE	IF	CITATIONS
109	Functional consequences of an LMNA mutation associated with a new cardiac and non-cardiac phenotype. <i>Human Mutation</i> , 2003, 21, 473-481.	2.5	66
110	A Comparison of the Effects of Carvedilol and Metoprolol on Well-Being, Morbidity, and Mortality (the "Patient Journey") in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1603-1611.	2.8	66
111	Mutations in the ANKRD1 gene encoding CARP are responsible for human dilated cardiomyopathy. <i>European Heart Journal</i> , 2009, 30, 2128-2136.	2.2	66
112	From abstract to impact in cardiovascular research: factors predicting publication and citation. <i>European Heart Journal</i> , 2012, 33, 3034-3045.	2.2	66
113	A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 1175-1182.	7.1	64
114	Prevalence of anemia in patients with chronic heart failure and their clinical characteristics. <i>Journal of Cardiac Failure</i> , 2004, 10, S1-S4.	1.7	63
115	Assessment of Long-Term Effects of Irbesartan on Heart Failure With Preserved Ejection Fraction as Measured by the Minnesota Living With Heart Failure Questionnaire in the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial. <i>Circulation: Heart Failure</i> , 2012, 5, 217-225.	3.9	63
116	Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. <i>European Journal of Heart Failure</i> , 2013, 15, 1296-1303.	7.1	63
117	Tolerability of carvedilol and ACE-inhibition in mild heart failure. Results of CARMEN (Carvedilol) Tj ETQq1 1 0.784314 rgBT /Overlock	7.1	62
118	Carvedilol Protects Better Against Vascular Events Than Metoprolol in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 49, 963-971.	2.8	62
119	International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: Data from the EuroHeart Failure Survey. <i>European Journal of Heart Failure</i> , 2007, 9, 292-299.	7.1	61
120	Homozygotes for a R869G Mutation in the β^2 -myosin Heavy Chain Gene have a Severe Form of Familial Hypertrophic Cardiomyopathy. <i>Journal of Molecular and Cellular Cardiology</i> , 2000, 32, 1575-1583.	1.9	59
121	Recall of lifestyle advice in patients recently hospitalised with heart failure: A EuroHeart Failure Survey analysis. <i>European Journal of Heart Failure</i> , 2007, 9, 1095-1103.	7.1	58
122	Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in <sc>SHIFT</sc>. <i>European Journal of Heart Failure</i> , 2014, 16, 810-816.	7.1	58
123	Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the <sc>SHIFT</sc> trial. <i>European Journal of Heart Failure</i> , 2015, 17, 1294-1301.	7.1	58
124	Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the <sc>SHIFT</sc> Holter substudy. <i>European Journal of Heart Failure</i> , 2015, 17, 518-526.	7.1	54
125	Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial). <i>American Journal of Cardiology</i> , 2015, 116, 1890-1897.	1.6	54
126	Baseline Plasma NT-proBNP and Clinical Characteristics: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Trial. <i>Journal of Cardiac Failure</i> , 2010, 16, 128-134.	1.7	53

#	ARTICLE	IF	CITATIONS
127	The Safety of Amiodarone in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2007, 13, 340-345.	1.7	52
128	Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-PRESERVE study. <i>European Journal of Heart Failure</i> , 2015, 17, 809-817.	7.1	52
129	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2019, 21, 974-984.	7.1	52
130	Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2009, 11, 85-91.	7.1	51
131	Predictors of short term mortality in heart failure – Insights from the Euro Heart Failure survey. <i>International Journal of Cardiology</i> , 2010, 138, 63-69.	1.7	51
132	Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. <i>Heart Failure Reviews</i> , 2013, 18, 107-122.	3.9	51
133	Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23. <i>European Heart Journal</i> , 2021, 42, 2000-2011.	2.2	49
134	Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure. <i>American Heart Journal</i> , 2003, 146, 729-735.	2.7	48
135	Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 303-323.	1.6	48
136	Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis. <i>European Journal of Heart Failure</i> , 2015, 17, 1182-1191.	7.1	48
137	Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. <i>American Journal of Cardiology</i> , 2000, 86, 417-421.	1.6	46
138	Efficacy and Safety of Ivabradine in Patients With Severe Chronic Systolic Heart Failure (from the Tj ETQqO O O rgBT /Overlock_10 Tf 50	1.6	45
139	Risk following hospitalization in stable chronic systolic heart failure. <i>European Journal of Heart Failure</i> , 2013, 15, 885-891.	7.1	42
140	The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. <i>European Journal of Heart Failure</i> , 2014, 16, 426-434.	7.1	42
141	Genotype-phenotype analysis in four families with mutations in β -myosin heavy chain gene responsible for familial hypertrophic cardiomyopathy. <i>Human Mutation</i> , 1998, 12, 385-392.	2.5	41
142	Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. <i>European Journal of Heart Failure</i> , 2018, 20, 373-381.	7.1	41
143	Apical left ventricular aneurysm without atrio-ventricular block due to a lamin A/C gene mutation. <i>European Journal of Heart Failure</i> , 2003, 5, 821-825.	7.1	39
144	A new polymorphism in human calmodulin III gene promoter is a potential modifier gene for familial hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2009, 30, 1648-1655.	2.2	39

#	ARTICLE	IF	CITATIONS
145	Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of <sc>SHIFT</sc>. European Journal of Heart Failure, 2016, 18, 1182-1189.	7.1	39
146	Clinical development of pharmacologic agents for acute heart failure syndromes: A proposal for a mechanistic translational phase. American Heart Journal, 2011, 161, 224-232.	2.7	38
147	Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. ESC Heart Failure, 2014, 1, 52-58.	3.1	38
148	Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: The SHIFT Risk Model. International Journal of Cardiology, 2015, 184, 163-169.	1.7	38
149	Heart rate and its reduction in chronic heart failure and beyond. European Journal of Heart Failure, 2017, 19, 1230-1241.	7.1	37
150	Muscular blood flow response to submaximal leg exercise in normal subjects and in patients with heart failure. Journal of Applied Physiology, 1996, 81, 2571-2579.	2.5	36
151	Comparative Value of Tissue Doppler Imaging and M-Mode Color Doppler Mitral Flow Propagation Velocity for the Evaluation of Left Ventricular Filling Pressure. Chest, 2005, 128, 2544-2550.	0.8	36
152	Effect of carvedilol and metoprolol on the mode of death in patients with heart failure. European Journal of Heart Failure, 2007, 9, 1128-1135.	7.1	36
153	Early identification of mutation carriers in familial hypertrophic cardiomyopathy by combined echocardiography and tissue Doppler imaging. European Heart Journal, 2010, 31, 1599-1607.	2.2	36
154	Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure, 2015, 17, 169-176.	7.1	36
155	Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. European Heart Journal, 2017, 38, ehw509.	2.2	36
156	History of Atrial Fibrillation as a Risk Factor in Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 960-966.	3.9	35
157	Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. Journal of Cardiac Failure, 2017, 23, 20-28.	1.7	35
158	Prevalence of Memory Disorders in Ambulatory Patients Aged ≥ 70 Years With Chronic Heart Failure (from the EFICARE Study). American Journal of Cardiology, 2014, 113, 1205-1210.	1.6	34
159	Cardiologists' awareness and perceptions of guidelines for chronic heart failure. The ADDRESS your Heart survey. European Journal of Heart Failure, 2008, 10, 1020-1025.	7.1	33
160	Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects. Journal of the American College of Cardiology, 2002, 39, 2034-2041.	2.8	32
161	Clinical trials in acute heart failure: simpler solutions to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round-table think tank on acute heart failure, 12 May 2009. European Journal of Heart Failure, 2011, 13, 1253-1260.	7.1	32
162	Pregnancy in women with a cardiomyopathy: Outcomes and predictors from a retrospective cohort. Archives of Cardiovascular Diseases, 2018, 111, 199-209.	1.6	32

#	ARTICLE	IF	CITATIONS
163	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. <i>Annals of Internal Medicine</i> , 2021, 174, 1065-1072.	3.9	32
164	Exchange of β -blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Tj ETQq0,0,0 rgBT /Overlock 10 Tf	7.1	29
165	EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). <i>European Heart Journal</i> , 2016, 37, 152-160.	2.2	29
166	Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes. <i>Diabetes Care</i> , 2011, 34, 1394-1396.	8.6	28
167	Sustainable Development Goals and the Future of Cardiovascular Health: A Statement From the Global Cardiovascular Disease Taskforce. <i>Journal of the American Heart Association</i> , 2014, 3, e000504.	3.7	28
168	Brain natriuretic peptide usefulness in very elderly dyspnoeic patients: the BED study. <i>European Journal of Heart Failure</i> , 2017, 19, 540-548.	7.1	28
169	Polymorphisms of genes of the cardiac calcineurin pathway and cardiac hypertrophy. <i>European Journal of Human Genetics</i> , 2003, 11, 659-664.	2.8	27
170	The future of clinical trials in secondary prevention after acute coronary syndromes. <i>European Heart Journal</i> , 2011, 32, 1583-1589.	2.2	27
171	Unresolved issues in the management of chronic stable angina. <i>International Journal of Cardiology</i> , 2015, 201, 200-207.	1.7	27
172	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.8	26
173	Exclusion of HRAS from long QT locus. <i>Nature Genetics</i> , 1994, 8, 113-114.	21.4	25
174	The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology: Guidelines for the Diagnosis and Treatment of Chronic Heart Failure: reply. <i>European Heart Journal</i> , 2005, 26, 2473-2474.	2.2	25
175	Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. <i>European Journal of Heart Failure</i> , 2012, 14, 1401-1409.	7.1	25
176	Molecular genetics in hypertrophic cardiomyopathy: towards individualized management of the disease. <i>Expert Review of Molecular Diagnostics</i> , 2006, 6, 65-78.	3.1	24
177	Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2013, 15, 79-84.	7.1	24
178	Familial dilated cardiomyopathy: clinical features in French families. <i>European Journal of Heart Failure</i> , 1999, 1, 353-361.	7.1	22
179	Severe dilated cardiomyopathy and quadriceps myopathy due to lamin A/C gene mutation: A phenotypic study. <i>European Journal of Heart Failure</i> , 2006, 8, 249-256.	7.1	22
180	Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure. <i>European Journal of Heart Failure</i> , 2013, 15, 1044-1052.	7.1	22

#	ARTICLE	IF	CITATIONS
181	Involvement of BAG3 and HSPB7 loci in various etiologies of systolic heart failure: Results of a European collaboration assembling more than 2000 patients. <i>International Journal of Cardiology</i> , 2015, 189, 105-107.	1.7	22
182	Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina. <i>Circulation: Heart Failure</i> , 2015, 8, 717-724.	3.9	22
183	Comparison of Outcome Adjudication by Investigators and by a Central End Point Committee in Heart Failure Trials. <i>Circulation: Heart Failure</i> , 2020, 13, e006720.	3.9	22
184	Consensus of the French Society of Gerontology and Geriatrics and the French Society of Cardiology for the management of coronary artery disease in older adults. <i>Archives of Cardiovascular Diseases</i> , 2009, 102, 829-845.	1.6	21
185	A novel genetic variant in the transcription factor Islet-1 exerts gain of function on myocyte enhancer factor 2C promoter activity. <i>European Journal of Heart Failure</i> , 2013, 15, 267-276.	7.1	21
186	Desmosomal Cadherins Are Decreased in Explanted Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patient Hearts. <i>PLoS ONE</i> , 2013, 8, e75082.	2.5	21
187	Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 478-486.	4.1	21
188	Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. <i>European Journal of Heart Failure</i> , 2016, 18, 672-683.	7.1	21
189	Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 418-427.	4.1	20
190	Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry. <i>ESC Heart Failure</i> , 2021, 8, 861-871.	3.1	20
191	Myocarditis during Acute Schistosomiasis in Two Travelers. <i>American Journal of Tropical Medicine and Hygiene</i> , 2010, 82, 365-367.	1.4	19
192	Screening of genes encoding junctional candidates in arrhythmogenic right ventricular cardiomyopathy/dysplasia. <i>Europace</i> , 2013, 15, 1522-1525.	1.7	19
193	Left atrial volume predicts abnormal exercise left ventricular filling pressure. <i>European Journal of Heart Failure</i> , 2014, 16, 1089-1095.	7.1	19
194	Thromboembolism in heart failure, old ideas and new challenges. <i>European Journal of Heart Failure</i> , 2001, 3, 265-269.	7.1	18
195	Design of the Heart failure Endpoint evaluation of All-Antagonist Losartan (HEAAL) study in patients intolerant to ACE-inhibitor. <i>European Journal of Heart Failure</i> , 2008, 10, 899-906.	7.1	18
196	Below-Knee Arterial Calcification in Type 2 Diabetes: Association With Receptor Activator of Nuclear Factor β Ligand, Osteoprotegerin, and Neuropathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4250-4258.	3.6	18
197	Patient journey in decompensated heart failure: An analysis in departments of cardiology and geriatrics in the Greater Paris University Hospitals. <i>Archives of Cardiovascular Diseases</i> , 2017, 110, 42-50.	1.6	18
198	Sustainable Development Goals and the Future of Cardiovascular Health: A Statement From the Global Cardiovascular Disease Taskforce. <i>Global Heart</i> , 2014, 9, 273.	2.3	18

#	ARTICLE	IF	CITATIONS
199	Genetic aspects of heart failure. <i>European Journal of Heart Failure</i> , 1999, 1, 121-126.	7.1	17
200	Long-term outcome after bare-metal or drug-eluting stenting for allograft coronary artery disease. <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, 316-322.	0.6	17
201	Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (lâ€PRESERVE) trial. <i>European Journal of Heart Failure</i> , 2016, 18, 1021-1031.	7.1	17
202	Identification of a Mutation Near a Functional Site of the Î² cardiac myosin Heavy Chain Gene in a Family with Hypertrophic Cardiomyopathy. <i>Journal of Molecular and Cellular Cardiology</i> , 1994, 26, 1241-1247.	1.9	16
203	Effects of Prolonged Propranolol Treatment on Left Ventricular Remodeling and Oxidative Stress After Myocardial Infarction in Rats. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 35, 806-813.	1.9	16
204	Doppler Echocardiography in Familial Hypertrophic Cardiomyopathy. <i>Echocardiography</i> , 1995, 12, 235-241.	0.9	14
205	A familial form of conduction defect related to a mutation in the PRKAG2 gene. <i>Europace</i> , 2007, 9, 597-600.	1.7	13
206	Genes and their polymorphisms in mono- and multifactorial cardiomyopathies. <i>Pharmacogenomics</i> , 2002, 3, 367-378.	1.3	12
207	Quality of Physician Adherence to Guideline Recommendations for Life-saving Treatment in Heart Failure: an International Survey. <i>Cardiac Failure Review</i> , 2017, 3, 130.	3.0	12
208	The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 377-387.	1.8	12
209	A Description of the Clinical Characteristics at Baseline of Patients Recruited into the Carvedilol or Metoprolol European Trial (COMET). <i>Cardiovascular Drugs and Therapy</i> , 2004, 18, 139-152.	2.6	11
210	Yearsâ€neededâ€toâ€treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials. <i>European Journal of Heart Failure</i> , 2009, 11, 256-263.	7.1	11
211	Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.. <i>ESC Heart Failure</i> , 2019, 6, 1199-1207.	3.1	11
212	Diagnostic accuracy of a 2D left ventricle hypertrophy score for familial hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2005, 26, 1882-1886.	2.2	10
213	Role of ivabradine in management of stable angina in patients with different clinical profiles. <i>Open Heart</i> , 2018, 5, e000725.	2.3	10
214	Familial and sporadic hypertrophic myopathy: differences and similarities in a genotyped population. A long follow-up study. <i>Revista Portuguesa De Cardiologia</i> , 2008, 27, 147-73.	0.5	10
215	The beat goes on: on the importance of heart rate in chronic heart failure. <i>European Heart Journal</i> , 2012, 33, 1044-1045.	2.2	7
216	The wealth of nations and the dissemination of cardiovascular research. <i>International Journal of Cardiology</i> , 2013, 169, 190-195.	1.7	7

#	ARTICLE	IF	CITATIONS
217	Asymptomatic left ventricular dysfunction in patients with type 2 diabetes free of cardiovascular disease and its relationship with clinical characteristics: The <scp>DIACAR</scp> cohort study. Diabetes, Obesity and Metabolism, 2021, 23, 434-443.	4.4	7
218	Genetics of familial hypertrophic cardiomyopathy. Trends in Cardiovascular Medicine, 1993, 3, 115-118.	4.9	6
219	Relationships between the antihypertensive effects of bisoprolol and levels of plasma atrial natriuretic peptide in hypertensive patients. Fundamental and Clinical Pharmacology, 2002, 16, 361-368.	1.9	6
220	Feasibility of outpatient coronary angiography with â€œad hocâ€•angioplasty. Archives of Cardiovascular Diseases, 2008, 101, 383-390.	1.6	5
221	Heart rate in chronic heart failure: an overlooked risk factor. European Heart Journal, 2015, 36, 648-649.	2.2	5
222	Sustainable Development Goals and the future of cardiovascular health. A statement from the Global Cardiovascular Disease Taskforce. European Heart Journal, 2014, 35, 3238-9.	2.2	5
223	How can the European Society of Cardiology ensure compliance with ethical standards?. European Heart Journal, 2016, 37, 741-744.	2.2	4
224	Liraglutide in heart failure: caution is needed. European Journal of Heart Failure, 2017, 19, 78-79.	7.1	4
225	Lâ€™Ã©ducation thÃ©rapeutique du patient (ETP), une piÃ©ce maÃ®tresse pour rÃ©pondre aux nouveaux besoins de lamÃ©decine. Bulletin De L'Academie Nationale De Medecine, 2013, 197, 1747-1781.	0.0	4
226	The heart of genomics. Nature Medicine, 2001, 7, 287-288.	30.7	3
227	Ivabradine and outcomes in chronic heart failure â€œ Authors' reply. Lancet, The, 2010, 376, 2069-2070.	13.7	3
228	Heart rate decrease: A new paradigm in the treatment of heart failure. Insights from the SHIFT study. Archives of Cardiovascular Diseases, 2011, 104, 67-69.	1.6	3
229	Effect of Ivabradine onÃ©arly Readmissions After Hospitalization for Worsening Heart Failure. JACC: Heart Failure, 2015, 3, 268-269.	4.1	3
230	ESSENTIAL â€œ The Studies of Oral Enoximone Therapy in Advanced Heart Failure. Journal of Cardiac Failure, 2005, 11, 721.	1.7	2
231	Treatment of advanced chronic heart failure with normal left ventricular ejection fraction. Response to the letter by Dr. Martinezâ€™elles. European Journal of Heart Failure, 2007, 9, 1224-1225.	7.1	2
232	Pretest probability of a normal echocardiography: Validation of a simple and practical algorithm for routine use. Archives of Cardiovascular Diseases, 2014, 107, 105-111.	1.6	2
233	Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 1064-1071.	0.9	2
234	The year in cardiology 2015: heart failure. European Heart Journal, 2016, 37, 437-441.	2.2	2

#	ARTICLE	IF	CITATIONS
235	Financial impact of ivabradine on reducing heart failure penalties under the Hospital Readmission Reduction Program. <i>Current Medical Research and Opinion</i> , 2017, 33, 185-191.	1.9	2
236	Are angiotensin II receptor antagonists indicated in chronic heart failure?. <i>Heart Failure Monitor</i> , 2002, 2, 85-7.	0.7	2
237	Join us. <i>European Journal of Heart Failure</i> , 2002, 4, 1-1.	7.1	1
238	Championing cardiovascular health innovation in Europe. <i>Acta Cardiologica</i> , 2013, 68, 650-655.	0.9	1
239	Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. <i>ESC Heart Failure</i> , 2014, 1, n/a-n/a.	3.1	1
240	Diab�te et insuffisance cardiaque : donn�es �pid�miologiques et implications th�rapeutiques.. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018, 202, 909-917.	0.0	1
241	Lessons from the European heart survey. <i>Circulation</i> , 2006, 113, f25-6.	1.6	1
242	The development of an international, common, prospective, cardiology database. Report of the joint G8 Cardio-Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO)–Societ� Fran�saise de Cardiologie (SFC) database committee. <i>Acute Cardiac Care</i> , 2009, 11, 113-20.	0.2	1
243	Spontaneous and evoked release of atrial natriuretic peptide from the rat atria in vitro. <i>Journal of the American College of Cardiology</i> , 1990, 15, A77.	2.8	0
244	Impact on mortality of plasma NT-proBNP in chronic heart failure in patients treated with beta-blockers. results from COMET. <i>Journal of Cardiac Failure</i> , 2004, 10, S77.	1.7	0
245	Health Related Quality of Life in I-PRESERVE Trial. <i>Journal of Cardiac Failure</i> , 2008, 14, S73.	1.7	0
246	Predicting Adverse Effects during Angiotensin Receptor Blocker Treatment in Heart Failure: Results from the HEAAL Trial. <i>Journal of Cardiac Failure</i> , 2010, 16, S73-S74.	1.7	0
247	Comments on meta-analysis of ivabradine as adjuvant treatment for chronic heart failure by Mizzaci et al.. <i>International Journal of Cardiology</i> , 2017, 239, 2.	1.7	0
248	Le point sur le dictionnaire de l�TMANM du 1er janvier 2015 au 26 septembre 2016. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2015, 199, 1493-1498.	0.0	0
249	Maladies rares, le mod�le fran�sais. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2016, 200, 979-991.	0.0	0
250	Efficacit� et effets ind�sirables des statines: �vidences et pol�miques. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018, 202, 817-835.	0.0	0
251	[Not Available]. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2015, 199, 835-847.	0.0	0